In a significant market development, shares of HIMS surged by 13%, increasing by $3.10, following the announcement that Novo Nordisk has agreed to distribute its products through the Hims platform. This agreement marks the end of a long-standing conflict between the two companies. Customers can expect to have access to popular weight-loss medications, including Novo Nordisk’s Ozempic and Wegovy injectables, along with the Wegovy pill, available on the Hims platform later this month.
According to HIMS, the agreement encompasses various formulations of semaglutide, with plans to introduce multiple strengths of the Ozempic injections and Wegovy medications. In the future, HIMS and Novo Nordisk aim to collaborate on additional product offerings, further diversifying the treatments available for providers on the Hims platform.
Meanwhile, the broader market is experiencing flat movements amid rising oil prices, geopolitical tensions, and inflation data. S&P 500 futures have increased by approximately 0.1%, while the Dow Jones Industrial Average dipped by 63 points. The Nasdaq remained flat, and the price of oil spiked by $3.55. Gold prices fell significantly, dropping by $53.57, while Bitcoin saw a decrease of $587.60.
The uptick in oil prices can be attributed to escalating tensions in the Strait of Hormuz, where Iran has intensified its military strikes, impacting multiple cargo ships. In response, the International Energy Agency (IEA) is proposing a historic release of 400 million barrels of oil from reserves to stabilize crude prices. This potential release would more than double the previous largest release from the IEA, which occurred following Russia’s invasion of Ukraine.
On the economic front, consumer prices rose by 2.4% on an annual basis, aligning with expectations. Monthly figures showed a 0.3% increase, with core inflation — excluding food and energy prices — also in line with predictions, at 0.2% for the month and an annual rate of 2.5%.
In notable stock market performances, Oracle shares jumped by 10%, or $15.26, after the company reported third-quarter earnings that exceeded expectations. For the third quarter, Oracle posted earnings of $1.79 per share—10 cents greater than forecasts—and revenue of $17.19 billion, which represented a 21.7% year-over-year increase. Significant growth in cloud revenue, reaching $8.9 billion and up 44% year-over-year, contributed to the positive outlook. Oracle has also raised its revenue guidance for the upcoming quarter, expecting between $18.93 billion and $19.24 billion, which surpasses analysts’ predictions.
Analysts have responded positively to Oracle’s performance, with some upgrading the stock to overweight and setting price targets as high as $320 per share. Overall, these developments reflect the dynamic nature of the market, driven by corporate earnings news and geopolitical factors.
